Search company, investor...

Total Raised

$234.15M

Investors Count

24

Funding, Valuation & Revenue

7 Fundings

Creative Biosciences has raised $234.15M over 7 rounds.

Creative Biosciences's latest funding round was a Series D for $86.96M on October 14, 2021.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/14/2021

Series D

$86.96M

$99M

0

FY undefined

7

9/27/2020

Series C

$99M

$99M

0

FY undefined

10

8/20/2019

Private Equity

$99M

0

FY undefined

10

4/12/2019

Series B

$99M

$99M

0

FY undefined

10

7/1/2017

Series A

$99M

$99M

0

FY undefined

10

Date

10/14/2021

9/27/2020

8/20/2019

4/12/2019

7/1/2017

Round

Series D

Series C

Private Equity

Series B

Series A

Amount

$86.96M

$99M

$99M

$99M

Investors

Valuation

$99M

$99M

$99M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

7

10

10

10

10

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Creative Biosciences Investors

24 Investors

Creative Biosciences has 24 investors. IDG Capital invested in Creative Biosciences's Series D funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/12/2019

10/14/2021

3
Series B, Series C (2020), Series D (2021)

Venture Capital

China

10/14/2021

10/14/2021

1
Series D

Venture Capital

China

10/14/2021

10/14/2021

1
Series D

Investment Bank

China

00/00/0000

00/00/0000

ABC International

Subscribe to see more

Investment Bank

Hong Kong

00/00/0000

00/00/0000

Alibaba.com

Subscribe to see more

Corporation

China

First funding

4/12/2019

10/14/2021

10/14/2021

00/00/0000

00/00/0000

Last Funding

10/14/2021

10/14/2021

10/14/2021

00/00/0000

00/00/0000

Investor

ABC International

Alibaba.com

Rounds

3
Series B, Series C (2020), Series D (2021)
1
Series D
1
Series D

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Investment Bank

Investment Bank

Corporation

Location

China

China

China

Hong Kong

China

Creative Biosciences Acquisitions

1 Acquisition

Creative Biosciences acquired 1 company. Their latest acquisition was HELIXGEN on March 31, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/31/2020

$99M

Acquired

2

Date

3/31/2020

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

2

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.